Phase

Compound

Indication

Study

Status

Phase III

Cadazolid

Clostridium difficile-associated diarrhea

IMPACT

Ongoing

Macitentan

Pediatric PAH

TOMORROW

Initiating

Macitentan

Portopulmonary hypertension (PoPH)

PORTICO

Ongoing

 

Macitentan

Fontan-palliated

RUBATO

Initiating

Ponesimod

Multiple sclerosis

OPTIMUM

Ongoing

Ponesimod

Multiple sclerosis

POINT

Ongoing

Phase II

 

 

 

 

Cenerimod

Systemic lupus erythematosus

- Ongoing  

Clazosentan

Reversal of vasospasm associated with aneurysmal subarachnoid hemorrhage  REVERSE Ongoing

Dual Orexin Receptor Antagonist 

Insomnia 

-

Ongoing

Endothelin Receptor Antagonist

Specialty cardiovascular disorders

-

Ongoing

Macitentan

Chronic thromboembolic pulmonary hypertension

MERIT

Complete

Phase Ib

Lucerastat

Fabry disease 

-

Complete

Phase I

 

 

 

 

 

 

 

 

 

 

 

 

 

New Chemical Entity

Cardiovascular disorders

-

Ongoing

New Chemical Entity

Inflammatory disorders -

Ongoing

Selective Orexin 1 Receptor Antagonist

Neurological disorders -

Ongoing

T-type Calcium Channel Blocker

Neurological disorders -

Ongoing

 

Territory Manager, Sales and Marketing, US 

 

"I find my work motivational because what I do each day can change patients' lives."